Search results
Results From The WOW.Com Content Network
The mechanism that induces Anti-Ro/SSA production in autoimmune disorders remains under study. [3] [8] Some proposed factors that may stimulate production are viral infection, treatment of cells with TNF-α, cellular apoptosis, and exposure to UV irradiation. [3] Anti-Ro/SSA is produced in the cytoplasm of cells in the epidermal layer of the ...
20823 Ensembl ENSG00000138385 ENSMUSG00000068882 UniProt P05455 P32067 RefSeq (mRNA) NM_003142 NM_001294145 NM_001110145 NM_009278 NM_001355265 RefSeq (protein) NP_001281074 NP_003133 NP_001103615 NP_033304 NP_001342194 Location (UCSC) Chr 2: 169.79 – 169.81 Mb Chr 2: 69.69 – 69.7 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Sjögren syndrome type B antigen (SS-B) also known ...
Reference ranges (reference intervals) for blood tests are sets of values used by a health professional to interpret a set of medical test results from blood samples. ...
The idea behind the "mixed" disease is that this specific autoantibody is also present in other autoimmune diseases such as systemic lupus erythematosus, polymyositis, scleroderma, etc. MCTD was characterized as an individual disease in 1972 by Sharp et al., [3] [4] and the term was introduced by Leroy [5] in 1980. [6]
Idiopathic multicentric Castleman disease (iMCD) is a subtype of Castleman disease (also known as giant lymph node hyperplasia, lymphoid hamartoma, or angiofollicular lymph node hyperplasia), a group of lymphoproliferative disorders characterized by lymph node enlargement, characteristic features on microscopic analysis of enlarged lymph node tissue, and a range of symptoms and clinical findings.
Anti-centromere antibodies (ACAs; often styled solid, anticentromere) are autoantibodies specific to centromere and kinetochore function. They occur in some autoimmune diseases , frequently in limited systemic scleroderma (formerly called CREST syndrome ), and occasionally in the diffuse form of scleroderma .
Anti-Scl-70 (also called anti-topoisomerase I after the type I topoisomerase target [1]) is an anti-topoisomerase antibody-type of anti-nuclear autoantibodies, seen mainly in diffuse systemic scleroderma (with a sensitivity of 28–70%), but is also seen in 10–18% of cases of the more limited form of systemic scleroderma called CREST syndrome. [2]
AOL latest headlines, entertainment, sports, articles for business, health and world news.